Nasdaq · Healthcare
Mereo BioPharma Group plc (MREO)
As-reported financials and recent SEC filings for Mereo BioPharma Group plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$500,000
Net income
$-41.9M
Net margin
—
Diluted EPS
$-0.05
ROE
-102.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|
| Revenue | $500,000 | $0 | $10.0M | $0 |
| Gross profit | — | — | — | — |
| Operating income | $-40.1M | $-47.4M | $-28.4M | $-54.4M |
| Net income | $-41.9M | $-43.3M | $-29.5M | $-42.2M |
| Diluted EPS | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G/A2026-05-15
View on EDGAR →8-K2026-05-14
View on EDGAR →SCHEDULE 13G2026-05-14
View on EDGAR →8-K/A2026-05-12
View on EDGAR →10-Q2026-05-12
View on EDGAR →8-K2026-05-12
View on EDGAR →ARS2026-04-09
View on EDGAR →DEF 14A2026-04-09
View on EDGAR →Largest Healthcare peers
Go deeper on MREO
Search Mereo BioPharma Group plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.